Tilarginine acetate injection regulatory update

FDA granted Orphan Drug designation to Tilarginine acetate injection (TAI) to treat cardiogenic shock. Arginox will begin the international Phase III TRIUMPH trial of the nitric oxide (NO) synthase i...